From Precision press release (my emphasis in bold):
" Imugene will assume ongoing clinical execution for azer-cel in the large B-cell lymphoma (LBCL) population who have relapsed following autologous CAR T treatment. The license also includes an option to develop up to three other cancer research programs in the future."; and
"For azer-cel, Precision is eligible to receive up to $198 million in additional milestone payments and double-digit royalties on net sales. For each additional research program selected by Imugene, Precision is eligible for up to $145 million in milestone payments and tiered royalties on net sales."
Thats about $1 billion AUD in milestone payments if Imugene exercise the additional 3 programs, plus royalties on all programs.
Ann: Investor Webinar featuring COO, Dr Glover & CMO, Dr Woodard, page-242
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.2¢ |
Change
0.001(1.41%) |
Mkt cap ! $527.0M | |||
| Open | High | Low | Value | Volume |
| 7.2¢ | 7.6¢ | 7.1¢ | $2.390M | 32.54M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 1642723 | 7.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.3¢ | 68400 | 1 |
View Market Depth
| Last trade - 16.10pm 17/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.3¢ |
Change
0.001 ( 2.24 %) |
||||
| Open | High | Low | Volume | ||
| 7.1¢ | 7.6¢ | 7.1¢ | 9279379 | ||
| Last updated 15.58pm 17/05/2024 ? | |||||
| IMU (ASX) Chart |